Updated:
Treace Medical Concepts
Treace Medical Concepts, founded by John Treace, commercializes the Lapiplasty system for bunion correction and generated $190M in 2023 revenue.
Treace Medical Concepts
Treace Medical Concepts was founded in 2013 by John T. Treace, a veteran of the orthopedic implant industry who previously co-founded and sold a surgical-device company to Stryker. The firm's sole commercial focus is advancing the standard of care for hallux valgus, commonly known as bunions, a condition affecting an estimated 65 million Americans. The company went public on the Nasdaq in April 2021, raising $175 million in an initial public offering led by J.P. Morgan, BofA Securities, and SVB Leerink (per SEC filings, 2021). Treace commercializes the Lapiplasty 3D Bunion Correction system, a procedure that corrects the deformity in all three anatomical planes using patented instrumentation and titanium plating. The company's R&D pipeline also includes the Adductoplasty system for midfoot correction, cleared by the FDA in 2022, and the SpeedPlate rapid compression implants. Direct sales representatives market these technologies to foot-and-ankle orthopedic surgeons across the United States. Revenue has grown from $43 million in 2020 to $190 million in 2023, driven by surgeon training programs and patient-awareness campaigns that highlight the lower recurrence rates compared to traditional osteotomies (per the firm's annual report, 2023). The company employs a vertically integrated commercial model with a growing direct sales force, supported by a medical education platform called the Lapiplasty Proficiency Program. Treace opened a 30,000-square-foot headquarters and training facility in Ponte Vedra, Florida, in 2019. In January 2024 the company announced preliminary fourth-quarter 2023 revenue of $60.8 million to $62.8 million, representing roughly 20% year-over-year growth, affirming continued market share expansion in the bunion surgery segment (per the firm, January 2024). Unlike diversified orthopedic conglomerates — Stryker, Zimmer Biomet, Johnson & Johnson — Treace is a pure-play foot-and-ankle company competing through clinical specialization and patient-targeted marketing rather than broad portfolio bundling. Investors track the company's conversion of the addressable surgical market, not traditional asset-based metrics. Market share gains depend on surgeon adoption and randomized clinical data supporting lower recurrence; the ALIGN3D post-market study enrolled its first patient in 2022 and is central to Treace's long-term differentiation from generic osteotomy plates and wires.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Ponte Vedra
Corporate office
Ponte Vedra, FL, United States
Principals
John T. Treace
CEO and Founder
Sector focus
Frequently asked questions
What is the clinical advantage of the Lapiplasty system over traditional bunion surgery?
Lapiplasty corrects the unstable joint at the root of the bunion in three dimensions, whereas traditional osteotomies typically address only the cosmetic bump in two planes. The firm's clinical literature reports a 97% to 99% maintenance of correction at 24 months, compared to recurrence rates as high as 70% for traditional procedures noted in peer-reviewed studies. The procedure uses titanium plating technology patented by Treace to secure the tarsometatarsal joint after repositioning.
Is Treace Medical Concepts a single-family office or an operating company?
Treace Medical Concepts is a publicly traded medical-device company (Nasdaq: TMCI), not a family office or investment vehicle. It is included here because its name appeared in an entity screening context. The company designs, manufactures, and markets surgical systems directly to orthopedic surgeons, with all revenue derived from product sales.
How does Treace generate revenue and what is its commercial reach?
Treace sells its implants and instrumentation directly to hospitals, ambulatory surgery centers, and individual surgeons through a team of direct sales representatives in the United States. The company does not license its technology or operate through distributors. In 2023, it reported revenue of roughly $190 million, up from $143 million in 2022, driven by higher surgical volumes and an expanding active surgeon base.
Who are Treace's main competitors in foot-and-ankle orthopedics?
Treace competes with the foot-and-ankle divisions of large orthopedic companies including Stryker, Arthrex, and Zimmer Biomet, as well as smaller focused players like Paragon 28 and CrossRoads Extremity Systems. The company differentiates by dedicating its entire R&D and sales effort to midfoot and forefoot surgery rather than offering a broad extremity portfolio.
What is the regulatory status of Treace's product portfolio?
The Lapiplasty system received FDA 510(k) clearance in 2014 and its most recent clearance for expanded indications came in 2020. The Adductoplasty system for midfoot correction was cleared in 2022. All products are marketed under FDA Class II designations for bone fixation instrumentation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: